<DOC>
	<DOCNO>NCT00332605</DOCNO>
	<brief_summary>The goal propose study evaluate efficacy safety N-Acetyl Cysteine ( NAC ) combination naltrexone methamphetamine dependence .</brief_summary>
	<brief_title>N-Acetyl Cysteine Plus Naltrexone Methamphetamine Dependence</brief_title>
	<detailed_description>Forty subject DSM-IV methamphetamine dependence receive 8 week double-blind combination medication ( NAC plus naltrexone ) placebo . The hypothesis test NAC plus naltrexone effective well tolerated patient methamphetamine dependence compare placebo . The propose study provide need data treatment public health crisis currently lack clearly effective treatment .</detailed_description>
	<mesh_term>Methamphetamine</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1. men woman age 1865 2. current DSMIV methamphetamine dependence . 1. unstable medical illness 2. history seizure 3. myocardial infarction within 6 month 4. current pregnancy lactation , inadequate contraception woman childbearing potential 5. thought suicide 6. lifetime history DSMIV bipolar disorder type I , dementia , schizophrenia DSMIV psychotic disorder 7. previous treatment NAcetyl Cysteine naltrexone 8. treatment investigational medication depot neuroleptic within 3 month , fluoxetine within 6 week , psychotropics within 2 week prior study baseline 9. abnormal liver function test screen 10. diagnosis asthma 11. current use opiate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Methamphetamine Dependence</keyword>
</DOC>